EFEK EKSTRAK ETANOLIK RIMPANG TEMU KUNCI (Boesenbergia pandurata) TERHADAP AKTIVITAS SITOTOKSIK DOKSORUBISIN PADA SEL KANKER KOLON WiDr

Lina, Ramadhani Anan Asrawi (2018) EFEK EKSTRAK ETANOLIK RIMPANG TEMU KUNCI (Boesenbergia pandurata) TERHADAP AKTIVITAS SITOTOKSIK DOKSORUBISIN PADA SEL KANKER KOLON WiDr. Skripsi thesis, Universitas Wahid Hasyim Semarang.

Preview	Text COVER.pdf Download (1MB) | Preview
Preview	Text BAB I.pdf Download (306kB) | Preview
	Text BAB II.pdf Restricted to Registered users only Download (388kB)
	Text BAB III.pdf Restricted to Registered users only Download (637kB)
	Text BAB IV.pdf Restricted to Registered users only Download (215kB)
Preview	Text LAMPIRAN.pdf Download (2MB) | Preview
Preview	Text DAFTAR PUSTAKA.pdf Download (262kB) | Preview

Abstract

Doxorubicin a chemotherapy agent used generally in cancer treatment either singly or in combination. The use high doses of doxorubicin in therapy can lead to side effect and drug resistance, thus needs necessary to combine with cocchemotherapy agent one of the temu kunci rhizome extract that are proven to contain Panduratin A compounds and has cytotoxic activity. This study aims to determine the potential of cytotoxic combination of ethanolic temu kunci rhizome (Boesenbergia pandurata) (EERTK) and doxorubicin in colon cancer cell WiDr. Temu kunci rhizome extract use ethanol solvent by maceration method. Single cytotoxic activity and a combination ethanolic extract of temu kunci rhizome and doxorubicin were test used MTT assay method. The result of the test data was the percentage of cell viability. Data analysis used probit method. The combination of EERTK-doxorubicin use a ratio of and of the value of IC 50 obtained. Combined test data was further interpreted use Combination Index (CI). The combination ethanolic extract of Temu kunci and doxorubicin showed a strong synergistic effect with a CI score of 0.3 in the concentration ratio ( and ) of EERTK combination and doxorubicin. Based on the results of this study it can be concluded that EERTK has the potential to be developed as a coccemotherapy agent in colon cancer.

Actions (login required)

View Item